Dashboard
Manage Tickers

LXEOLexeo Therapeutics, Inc.

Nasdaq www.lexeotx.com


$ 9.55 $ -0.04 (-0.42 %)    

Tuesday, 17-Sep-2024 15:59:54 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.83 $ -2.14 (-0.45 %)
DIA $ 417.12 $ -0.26 (-0.06 %)
SPY $ 563.14 $ 0.30 (0.05 %)
TLT $ 100.82 $ -0.51 (-0.5 %)
GLD $ 237.35 $ -1.31 (-0.55 %)
$ 9.59
$ 9.61
$ 9.54 x 200
-- x --
$ 9.44 - $ 9.87
$ 9.00 - $ 22.33
241,814
na
317.06M
$ 2.07
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-11-2024 12-31-2023 10-K
4 12-11-2023 09-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

chardan-capital-maintains-buy-on-lexeo-therapeutics-maintains-23-price-target
Chardan Capital Maintains Buy on Lexeo The...
08/14/2024 10:40:53

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $23 price target.

hc-wainwright--co-maintains-buy-on-lexeo-therapeutics-lowers-price-target-to-21
HC Wainwright & Co. Maintains Buy on Lexeo...
08/13/2024 18:22:47

HC Wainwright & Co. analyst Mitchell Kapoor maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and lowers the price t...

rbc-capital-reiterates-outperform-on-lexeo-therapeutics-maintains-24-price-target
RBC Capital Reiterates Outperform on Lexeo...
08/13/2024 16:44:27

RBC Capital analyst Luca Issi reiterates Lexeo Therapeutics (NASDAQ:LXEO) with a Outperform and maintains $24 price target.

lexeo-therapeutics-q2-2024-gaap-eps-064-beats-069-estimate-cash-and-cash-equivalents-of-175m-expected-to-provide-operational-runway-into-2027
Lexeo Therapeutics Q2 2024 GAAP EPS $(0.64...
08/12/2024 11:22:59

hc-wainwright--co-reiterates-buy-on-lexeo-therapeutics-maintains-22-price-target
HC Wainwright & Co. Reiterates Buy on Lexe...
07/16/2024 12:08:12

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $22 pri...

chardan-capital-maintains-buy-on-lexeo-therapeutics-maintains-23-price-target
Chardan Capital Maintains Buy on Lexeo The...
07/16/2024 02:46:40

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $23 price target.

crude-oil-moves-lower-goldman-sachs-posts-upbeat-results
Crude Oil Moves Lower; Goldman Sachs Posts...
07/15/2024 18:32:44

why-solaredge-shares-are-trading-lower-by-12-here-are-other-stocks-moving-in-mondays-mid-day-session
Why SolarEdge Shares Are Trading Lower By ...
07/15/2024 17:23:20

nasdaq-surges-over-1-lexeo-therapeutics-shares-plummet
Nasdaq Surges Over 1%; Lexeo Therapeutics ...
07/15/2024 16:05:30

dow-jumps-over-200-points-ny-empire-state-manufacturing-index-falls-in-july
Dow Jumps Over 200 Points; NY Empire State...
07/15/2024 13:47:57

lexeo-therapeutics-report-interim-data-of-lx2006-for-treatment-of-friedreich-ataxia-cardiomyopathy-says-lx2006-was-well-tolerated-with-no-treatment-related-serious-adverse-events
Lexeo Therapeutics Report Interim Data Of ...
07/15/2024 10:07:43

Across both the Lexeo SUNRISE-FA Phase 1/2 clinical trial and the Weill Cornell Medicine investigator-initiated Phase 1A trial,...

lexeo-therapeutics-to-host-investor-webcast-to-report-interim-phase-12-clinical-data-of-lx2006-for-the-treatment-of-friedreich-ataxia-cardiomyopathy-on-monday-july-15-2024
Lexeo Therapeutics To Host Investor Webcas...
07/11/2024 12:21:11

Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for geneti...

baird-initiates-coverage-on-lexeo-therapeutics-with-outperform-rating-announces-price-target-of-28
Baird Initiates Coverage On Lexeo Therapeu...
06/13/2024 09:15:08

Baird analyst Brian Skorney initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Outperform rating and announces Pr...

hc-wainwright--co-initiates-coverage-on-lexeo-therapeutics-with-buy-rating-announces-price-target-of-22
HC Wainwright & Co. Initiates Coverage On ...
06/06/2024 10:41:43

HC Wainwright & Co. analyst Mitchell Kapoor initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Buy rating and...

matterport-sea-limited-ingevity-and-other-big-stocks-moving-higher-on-monday
Matterport, Sea Limited, Ingevity And Othe...
04/22/2024 14:10:39

lexeo-therapeutics-announces-in-license-agreement-with-cornell-university-to-expedite-development-of-lx2006-for-treatment-of-friedreich-ataxia-cardiomyopathy-under-agreement-co-has-acquired-certain-rights1-including-rights-to-current-and-future-data-generated-in-an-ongoing-investigator-initiated-phase-1a-trial-of-aavrh10hfxn-to-treat-fa-cardiomyopathy
Lexeo Therapeutics Announces In-License Ag...
04/22/2024 11:32:21

lexeo-therapeutics-shares-are-trading-higher-after-the-company-announced-it-was-granted-fda-fast-track-designation-for-lx2006-an-aavrh10hfxn-based-gene-therapy-candidate-for-the-treatment-of-friedreichs-ataxia-cardiomyopathy
Lexeo Therapeutics shares are trading high...
04/16/2024 11:37:09

lexeo-therapeutics-granted-fda-fast-track-designation-for-lx2006-aav-based-gene-therapy-candidate-for-the-treatment-of-friedreichs-ataxia-cardiomyopathy
Lexeo Therapeutics Granted FDA Fast Track ...
04/16/2024 11:31:58

rbc-capital-maintains-outperform-rating-for-lexeo-therapeutics-heres-what-you-need-to-know
RBC Capital Maintains Outperform Rating fo...
03/12/2024 17:00:15

rbc-capital-maintains-outperform-on-lexeo-therapeutics-raises-price-target-to-24
RBC Capital Maintains Outperform on Lexeo ...
03/12/2024 15:29:52

RBC Capital analyst Luca Issi maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Outperform and raises the price target from ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION